Download PDF
Klin Padiatr 2013; 225(S 01): 94-96
DOI: 10.1055/s-0033-1337970
Zum 80. Geburtstag von Prof. Riehm
© Georg Thieme Verlag KG Stuttgart · New York

Stem Cell Transplantation

Stammzelltransplantation
D. Niethammer
1   Pediatric Hospital, University of Tübingen, Germany
,
P. Bader
2   University Hospital for Children and Adolescents, Goethe University, Frankfurt, Germany
,
R. Handgretinger
1   Pediatric Hospital, University of Tübingen, Germany
,
T. Klingebiel
2   University Hospital for Children and Adolescents, Goethe University, Frankfurt, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
22 May 2013 (online)

Also available at
    Permissions and Reprints

Abstract

Stem cell transplantation in pediatric patients with leukemia has been a matter of debate since the first successful transplantation in a child with aplastic anemia in Germany in 1975. Since then, there has been a long way to implement fully stem cell transplantation strategies into the treatment studies organized within BFM Groups for first line or second line treatment of acute and chronic leukemias and myelodysplastic syndrome. The role of different risk groups, different donors, stem cell sources and alternative approaches as haploidentical transplantation as well have been studied as the impact of chimerism and minimal residual disease. Finally, for all leukemias and myelosdysplastic syndromes integrated treatment pathways have been developed, which integrate stem cell transplantation on an evidence base into the treatment of the patient.

Zusammenfassung

Die Rolle der Stammzelltransplantation für die Behandlung von Kindern mit Leukämien ist Gegenstand intensiver Debatten, seit 1975 in Deutschland das erste Kind mit einer aplastischen Anämie erfolgreich mit einer Knochenmarktransplantation behandelt wurde. Seitdem ist ein langer Weg zurückgelegt worden bis zu vollständigen Integration der Stammzelltransplantation in die Behandlungsstudien, die von BFM-Gruppen für die Erst- oder Zweitlinien-therapie von Kindern mit akuten und chronischen Leukämien und myelodysplastischen Syndromen organisiert werden. In zahlreichen Studien wurden die Rolle der Risikogruppen, der möglichen verschiedenen Spender, der verschiedenen Stammzellquellen und alternativer Ansätze wie der haploidentischen Transplantation ebenso untersucht wie der Einfluss von Chimärismus und minimaler Restkrankheit auf das Ergebnis der Transplantation. Heute existieren für alle Leukämien und myelodysplatischen Syndrome im Kindesalter integrierte Behandlungspfade, die auf einer Evidenz-basierten Grundlage die Stammzelltransplantion in die Behandlung des Patienten integrieren.

Key words

acute lymphoblastic leukemia - acute myelogeneic leukemia - chronic myeloid leukemia - myelodysplastic syndrome - stem cell transplantation - history - actual results

Schlüsselwörter

akute lymphoblaste Leukämie - chronische myelogene Leukämie - myelodysplatisches Syndrom - Stammzelltransplantation - Historie
 

  • References

  • 1 Al-Kasim FA, Thornley I, Rolland M et al. Single-centre experience with allogeneic bone marrow transplantation for acute lymphoblastic leukemia in childhood: similar survival after matched-related and matched-unrelated donor transplants. Br J Haematol 2002; 116: 483-490
    CrossrefPubMedGoogle Scholar
  • 2 Aridolina J, Neudorf S, Corey S. How I treat childhood CML. Blood 2012; 119: 1821-1830
    CrossrefPubMedGoogle Scholar
  • 3 Bader P, Hoelle W, Handgretinger R et al. Mixed hematopoetic chimerism after allogeneic bone marrow transplantation: the impact of quantitative PCR analysis for prediction of relapse and graft rejection in children. Bone Marrow Transplant 1997; 19: 697-702
    CrossrefPubMedGoogle Scholar
  • 4 Bader P, Stoll K, Huber S et al. Characterization of lineage-specific chimaerism in patients with acute leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation before and after relapse. Brit J Haematol 2000; 108: 761-768
    CrossrefPubMedGoogle Scholar
  • 5 Bader P, Kreyenberg H, Hoelle W et al. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?. J Clin Oncol 2004; 22: 1696-1706
    CrossrefPubMedGoogle Scholar
  • 6 Bader P, Kreyenberg H, Henze G et al. Predictive value of MRD monitoring after allogeneic SCT in relapsed childhood acute lymphoblastic leukemia: analysis of the ALL-REZ BFM Group. Bone Marrow Transplant 2009; 43 (Suppl.1): 40
    PubMedGoogle Scholar
  • 7 Barfield RC, Otto M, Houston J et al. A one-step large-scale method for T- and B-cell depletion of mobilized PBSC for allogeneic transplantation. Cytotherapy 2004; 6: 1-6
    CrossrefPubMedGoogle Scholar
  • 8 Barrios M, Jimenez-Velasco A, Roman-Gomez J et al. Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia. Haematologica 2003; 88: 801-810
    PubMedGoogle Scholar
  • 9 Benesch M, Urban C, Sykora KW et al. Transplantation of highly purified CD34+ progenitor cells from alternative donors in children with refractory severe aplastic anaemia. Br J Haematol 2004; 125: 58-63
    CrossrefPubMedGoogle Scholar
  • 10 Borgmann A, von Stackelberg A, Hartmann R et al. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in second remission: a matched-pair analysis. Blood 2003; 101: 3835-3839
    CrossrefPubMedGoogle Scholar
  • 11 Chaleff S, Otto M, Barfield RC et al. A large-scale method for the selective depletion of alphabeta T lymphocytes from PBSC for allogeneic transplantation. Cytotherapy 2007; 9: 746-754
    CrossrefPubMedGoogle Scholar
  • 12 Creutzig U, van den Heuvel-Elbrink M, Gibson B et al. Diagnosis and management of acute myelogenic leukemia in children and adolescents: recommendations from an international expert panel, on behalf of the AML Committee of the international BFM Study Group. Blood 2012; Prepublished online August 9, 2012 DOI: 10.1182/blood-2012-03-362608.
    PubMedGoogle Scholar
  • 13 Dopfer R, Henze G, Bender-Götze C et al. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM and CoALL-protocols: Results of the German Cooperative Study. Blood 1991; 78: 2780-2784
    PubMedGoogle Scholar
  • 14 Dufort G, Pisano S, Incoronato A et al. Feasibility and outcome of haploidentical SCT in pediatric high-risk hematologic malignancies and Fanconi anemia in Uruguay. Bone Marrow Transplant 2012; 47: 663-668
    CrossrefPubMedGoogle Scholar
  • 15 Eapen M, Rubinstein P, Zhang MJ et al. Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. J Clin Oncol 2006; 24: 145-151
    CrossrefPubMedGoogle Scholar
  • 16 Fernadez-Aviles F, Urbano-Ispizua A, Aymerich M et al. Serial quantification of lymphoid and myeloid mixed chimerism using multiplex PCR amplification of short tandem repeat markers predicts graft rejection and relapse, respectively, after allogeneic transplantation of CD 34+ selected cells from peripheral blood. Leukemia 2003; 17: 613-620
    PubMedGoogle Scholar
  • 17 Formankova R, Sedlacek P, Krskova L et al. Chimerism-directed adoptive immunotherapy in prevention and treatment of post-transplant relapse of leukemia in childhood. Heamatologica 2003; 88: 117-118
    PubMedGoogle Scholar
  • 18 Gustafsson A, Remberger M, Winiarski J et al. Unrelated bone marrow transplantation in children: outcome and a comparison with sibling donor grafting. Bone Marrow Transplant 2000; 25: 1059-1065
    CrossrefPubMedGoogle Scholar
  • 19 Handgretinger R, Klingebiel T, Lang P et al. Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant 2001; 27: 777-783
    CrossrefPubMedGoogle Scholar
  • 20 Handgretinger R, Chen X, Pfeiffer M et al. Feasibility and outcome of reduced-intensity conditioning in haploidentical transplantation. Ann N Y Acad Sci 2007; 1106: 279-289 Epub@2007 Apr 18:279–289
    CrossrefPubMedGoogle Scholar
  • 21 Hasle H, Niemeyer CM, Chessels JM et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferatie diseases. Leukemia 2003; 17: 277-282
    CrossrefPubMedGoogle Scholar
  • 22 Henslee-Downey PJ, Abhyankar SH, Parrish RS et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 1997; 89: 3864-3872
    PubMedGoogle Scholar
  • 23 Kardos G, Baumann I, Passmore SJ et al. Refractory anemia in childhood: A retrospective analysis of 67 patients with particular reference to monosomy 7. Blood 2003; 102: 1997-2003
    CrossrefPubMedGoogle Scholar
  • 24 Kaspers G, Creutzig U. Pediatric acute mayeloic leukemia:international progress and future directions. Leukemia 2005; 19: 2025-2029
    CrossrefPubMedGoogle Scholar
  • 25 Knechtli C, Goulden N, Hancock J et al. Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia. Br J Haematol 1998; 102: 860-871
    CrossrefPubMedGoogle Scholar
  • 26 Klingebiel T, Cornish J, Labopin M et al. Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood 2010; 115: 3437-3446
    CrossrefPubMedGoogle Scholar
  • 27 Klusmann J-H, Reinhardt D, Zimmermann M et al. The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myelogenic leukemis: results from the AML-BFM 98 study. Haematologica 2012; 97: 21-91
    CrossrefPubMedGoogle Scholar
  • 28 Lang P, Handgretinger R, Niethammer D et al. Transplantation of highly purified CD34+ progenitor cells from unrelated donors in pediatric leukemia. Blood 2003; 101: 1630-1636
    CrossrefPubMedGoogle Scholar
  • 29 Leung W, Lyengar R, Turner V et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 2004; 172: 644-650
    PubMedGoogle Scholar
  • 30 Leung W. Use of NK Cell activity in cure by transplant. Br J Haematol 2011; 155: 14-29
    CrossrefPubMedGoogle Scholar
  • 31 Leung W, Campana D, Yang J et al. High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood 2011; 118: 223-230
    CrossrefPubMedGoogle Scholar
  • 32 Luznik L, Fuchs EJ. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res 2010; 47: 65-77
    CrossrefPubMedGoogle Scholar
  • 33 Luznik L, O’Donnell PV, Symons HJ et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641-650
    CrossrefPubMedGoogle Scholar
  • 34 Locatelli F, Zecca M, Messina C et al. Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors. Leukemia 2002; 16: 2228-2237
    CrossrefPubMedGoogle Scholar
  • 35 Locatelli F, Nollke P, Zecca M et al. European Working Group on Childhood MDS; European Blood and Marrow transplantation group. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): Results of the EWOG-MDS/EBMT trial. Blood 2005; 105: 410-419
    CrossrefPubMedGoogle Scholar
  • 36 Niemeyer C, Dufffner U, Bender-Gotze C et al. AML-type intensive chemotherapy prior to stem cell transplantation (SCT) does not improve survival in children and adolescents with primary myelodysplastic syndromes (MDS). Blood 200 96: 521a
    PubMedGoogle Scholar
  • 37 Niewerth D, Creutzig U, Bierings M et al. A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood 2010; 116: 2205-2214
    CrossrefPubMedGoogle Scholar
  • 38 Oevermann L, Handgretinger R. New strategies for haploidentical transplantation. Pediatr Res 2012; 71: 418-426
    CrossrefPubMedGoogle Scholar
  • 39 Palma J, Salas L, Carrion F et al. Haploidentical stem cell transplantation for children with high-risk leukemia. Pediatr Blood Cancer 2012; 59: 895-901
    CrossrefPubMedGoogle Scholar
  • 40 Peters C, Schrauder A, Stackelberg A et al. Outcome of matched sibling donor SCT is equivalent to unrelated well matched donors HSCT. A report from the prospective international multicentre trial ALL-SCT-BFM 2003. Bone Marrow Transplant 2012; 47: S2 (abstr.)
    PubMedGoogle Scholar
  • 41 Pfeiffer MM, Feuchtinger T, Teltschik HM et al. Reconstitution of natural killer cell receptors influences natural killer activity and relapse rate after haploidentical transplantation of T- and B-cell depleted grafts in children. Haematologica 2010; 95: 1381-1388
    CrossrefPubMedGoogle Scholar
  • 42 Ravindranath Y, Yeager A, Chang M et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med 1996; 334: 1428-1434
    CrossrefPubMedGoogle Scholar
  • 43 Remberger M, Beelen DW, Fauser A et al. Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. Blood 2005; 105: 548-551
    CrossrefPubMedGoogle Scholar
  • 44 Sander A, Zimmermann M, Dworzak M et al. Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia 2010; 24: 1422-1428
    CrossrefPubMedGoogle Scholar
  • 45 Möricke A, Zimmermann M, Reiter A et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010 24. 265-284
    PubMedGoogle Scholar
  • 46 Schumm M, Lang P, Taylor G et al. Isolation of highly purified autologous and allogeneic peripheral CD34+cells using the CliniMACS device. J Hematother 1999; 8: 209-218
    CrossrefPubMedGoogle Scholar
  • 47 Stevens R, Hann I, Wheatly K et al. Marked improvement in outcome with chemotherapy alone in pediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council’s 10th AML trial. MRC Childhood Leukemia Working Party. Brit J Haematol 1998; 101: 130-140
    CrossrefPubMedGoogle Scholar
  • 48 Suttorp M, Eckardt L, Tauer J et al. Management of chronic myeloid leukemia in childhood. Curr Hematol Malig Rep 2012; 7: 116-124
    CrossrefPubMedGoogle Scholar
  • 49 Woods W, Neudorf S, Gold S et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001; 97: 56-62
    CrossrefPubMedGoogle Scholar